CPhI North America is part of the Informa Markets Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Did you know manufacturing of finished dosage is expected to grow at an average CAGR of 8.7% by 2020? Furthermore, North America forms a $50 billion formulations market, equating to a 31% market share. Impressive numbers to be sure, and the FDF Finished Drug Products Zone puts you right in the middle of this booming pharma market.

As the landscape continues to evolve with new business models, convergence between drugs and devices, pressure on generics, data intelligence, alternative medicines, single-use systems, and disposables, it can be a challenge to keep up. Not to mention increasing competition, quality compliance, and regulatory scrutiny making it trickier to drive business.

North America forms a $50 billion formulations market, equating to a 31% market share.

Manufacturing of finished dosage is expected to grow at an average CAGR of 8.7% from 2015 to 2020.

Increased demand for generics is expected to continue to rise given its high market penetration.

Increased global demand for affordable prescription and OTC drugs are forcing the industry to manufacture high levels of safe, high quality, and cost effective drugs efficiently.